Member Info for Moneymunch

GENFLOW BIOSCIENCES PLC

Released 07:00:11 11 February 2026

RNS Number : 4938S

Genflow Biosciences PLC

11 February 2026

Genflow Biosciences Plc

Notice of General Meeting

Genflow Biosciences Plc (LSE: GENF) (OTCQB: GENFF) ("Genflow" or the "Company"), a European-based biotechnology company focused on the development of gene therapies for age-related diseases, announces that the Board is considering potentially undertaking an equity raise which would be structured by issuing rights over the New Shares (in the form of shares or warrants) to new investors and/or existing shareholders in the Company for cash consideration in one or more private placements on a non-pre-emptive basis (the "Potential Equity Raise").

In order to facilitate the Potential Equity Raise and to ensure that it could be swiftly concluded if it progresses, the Board is seeking specific shareholder approval at a general meeting (the "General Meeting") for the allotment and issue of up to 188,947,368 new ordinary shares ("New Shares") (which is approximately 38% of the Company's current issued share capital) in connection with the Potential Equity Raise, on terms that the Board may determine.

In order for the Directors to issue New Shares free of statutory pre-emption rights, such statutory pre-emption rights must be dis-applied. Accordingly, the Board wishes to seek separate authorities to dis-apply pre-emption rights in respect of the allotment of the New Shares pursuant to the Potential Equity Raise.

The General Meeting will be held at One Heddon Street, London, W1B 4BD at 11am on 2 March 2026.

At this time, there is no certainty that the Potential Equity Raise will proceed and at this point no investors have entered into any agreements to subscribe for New Shares and the amounts and price of any Potential Equity Raise have not been agreed. To the extent that any money is raised from the Potential Equity Raise, it would be applied towards:

· Moving the MASH program to IND-enabling stage;

· Animal health: final payment to the contract research organization for the randomized clinical trial in aged beagle dogs and licensing effort;

· Glaucoma Proof of Concept studies and Business development effort; and

· Final phase of EU patent approval and continued processing of US patent applications

If the authorities sought at the General Meeting in connection with the Potential Equity Raise are approved, the Directors shall have discretion to determine the terms of the Potential Equity Raise, including the number of New Shares and warrants to be issued (subject to the limits of the authorities) and the price at which the New Shares will be issued, as well as the identity of who the New Shares will be issued to. Further details of the Potential Equity Raise (if it proceeds) will be announced in due course.

My thoughts exactly pickedpeck, Eric did say he was expecting initial readout efficacy data by end of January, and so hopefully being shared with the Animal Healthcare companies as they finalise their due diligence. Fingers crossed!!! Gl :-)

Can't imagine Eric speaking on Monday about Genflow's innovative approach using companion animal trials as a bridge to human therapeutics, if he had an inkling initial Efficacy Data on the Dog Trial wasn't positive. Gla holders;-)

Overview

Dive into how Genflow Biosciences is turning longevity research into treatments that could be applied at the bedside

Genflow Biosciences: Translating longevity research to the bedside

Join us for an evening with Dr. Eric Leire, CEO and Founder of Genflow Biosciences, as we explore the challenges and innovations in longevity therapeutics.

🧬 About the Speaker

Dr. Eric Leire is CEO of Genflow Biosciences(LSE: GENF), the first longevity-focused biotech company to list on the London Stock Exchange. Genflow develops gene therapies targeting the molecular hallmarks of aging, with a focus on a centenarian variant of the SIRT6 gene critical for DNA repair and genomic stability.

With over 20 years of pharma and biotech experience, including leadership roles at Enochian Biosciences and Aptorum Group, Dr. Leire is an expert in Advanced Therapy Medicinal Products (ATMPs). He has guided multiple gene therapy assets from discovery through clinical development. He holds an MD from the University of Grenoble and an MBA from HEC Paris and Kellogg School of Management.

🧠 About the Talk

Why have decades of aging research yielded so few clinical treatments? Dr. Leire will examine the "translational gap" in longevity science, exploring the limitations of traditional murine models, regulatory frameworks shaping the industry, and Genflow's innovative approach using companion animal trials as a bridge to human therapeutics.

🧠 About the Societies

This event is co-hosted by the Oxford Society of Ageing and Longevity (OSAL) and the Oxford Personalised Medicine Society (OUPM). OSAL is a student-led initiative dedicated to highlighting cutting-edge ageing research and treatments that target the underlying biology of ageing, having previously hosted world-leading speakers including Professor George Church, Dr. Matt Kaeberlein (Dog Aging Project),and Andrew Steele (author of Ageless). OUPM serves as a platform for 1000+ students and faculty across all Oxford colleges to develop their interests in personalised medicine through education, discussion, and interdisciplinary research.

Genflow Biosciences (LON:G... + Follow 2.256 followers 7h

Genflow Biosciences (LON:GENF) (OTCQB:GENFF

CEO Dr. Eric Leire has been invited bv the Oxford Societv of Ageing and Longevity to speak on February 16th

As interest in genetic drivers of #aging continues ta grow, we're proud to see #Genflow's science and leadership recognized at the forefront of the field

#GENF #SIRT6 #biotech #agingbiology #Oxford #lifespan #longevity

Par for the course Dave, and nothing we haven't all seen before, especially in run up to potential game changing news, and you're always going to have sellers on an upturn in sp whether tactical or otherwise. All in the mix regardless, and now very much looking forward to the week ahead in excited anticipation. Gl.:-)))

Momentum in Britain’s biotech market

6 Feb, 2026

Biotechnology

Although 2025 was not without its challenges, there is growing momentum and increased investor confidence in the UK biotech sector.

......

The macro-environment going into 2026 should also bolster UK biotech. The Nasdaq ended last year at an all-time high, investor sentiment is strengthening, and the association says the UK-US pharmaceutical trade deal has reinforced confidence in the UK market.

Crucially, it adds, last year saw the policy foundations laid for a new era of domestic capital deployment – most notably the Life Sciences Sector Plan, the Mansion House reforms, and the first evidence of pension-backed investment into the sector through the Draig Therapeutics financing and Aviva investing in Cambridge Innovation Capital.

“We very much welcome the Mansion House Accord as a positive step in the right direction. Not only will it provide domestic scale-up capital for the most promising UK-based companies, it should also help boost returns for UK pensioners to be more in line with those seen in the US and Canada,” said James Costine, UK chief finance officer of SV Health Investors.

Momentum in Britain’s biotech market - Healthcare Today hTtps://share.google/1YEHDGDCcrGfGeXlx

All good things come to those who wait. Potential multiple material newsflow in the pipeline including the eagerly awaited initial Efficacy Data on the Dog Trial, expected imminently. Positive data will be a game-changer and every chance it will trigger a lucrative commercial licensing deal, which will be a company maker and transformational for all invested, and as it "worked like Magic in mice" , and if confirmed likewise in Dogs, then obviously a very high chance of translation to humans, which no doubt will grab the attention of every Major Pharma. The appointment of the new Chairman, with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets, speaks volumes, especially in this unprecedented period of frenzy of M&A activity by Major Pharma, which is expected to continue this year at pace. Exciting times and transformational UPside prospects and potential, and also great news the €4m non-dilutive grant funding has finally been signed off, ( i'd almost written it off, given how long we've waited), but with 2025 Development costs expected to be taken into account, we could have a couple of million Euro's winging its way into Genflow's bank account very soon!!!....On and most certainly UP!!! Gla holders :-)

And Primed!!! Gl ;-)

Exciting times for all invested, potential company making news on several fronts expected soon, which could propel Genflow into the Global market and investor spotlight , taking the sp to new highs, potentially multiples and multiples of the current bargain low entry opportunity. Gla holders, significant UPward momentum from now on in!!! :-)

I thought he looked confident and sounded bullish, potential game changing news along with a significant major re-rate, fast approaching !!! Gl ;-)))

Looking good for an UPward surge in sp and the last time we see sub 2p!!!??? Gla holders:-)

Something similar for Genflow, more than conceivable!!!! ;-)

2/2/26

Roche is continuing its return to the RNA space by paying $200 million for the worldwide license to one of SanegeneBio’s programs.

The companies didn’t specify which indication the program is focused on, only disclosing that it is derived from Sanegene’s RNAi platform. The Boston-based biotech will be responsible for early development activities before Roche’s Genentech unit takes over for clinical development and commercialization activities.

In return, Sanegene will receive the $200 million upfront payment and could be in line for up to $1.5 billion in development and commercialization milestone payments as well as tiered royalties on sales.

Along with the new Chairman, hence his appointment. Gl :-)

Berdugo’s expertise includes RNA-based therapeutics and lipid nanoparticle delivery technologies, which align with Genflow’s scientific platform development.

"His expertise in strategy, partnerships and financing as well as his deep experience with RNA-LNP technologies will be instrumental as we accelerate our programs and expand our global reach,"

Yes indeed Porter, and the buying continues in anticipation of company making news and a significant major re-rate!!! Gl :-)

Maybe a sell, although the trade directly before it on Monday at 4.06pm, was a bot trade sell for 97 shares at 1.8p, and so who knows??? All in the mix regardless and one day closer to potential game changing news. Gl :-)

A tightly coiled spring comes to mind, and not too long i reckon, before it's released. Gl :-)

Perfectly poised and primed Porter, sustained share accumulation for months!!! Gl :-)

Yes indeed pickedpeck, very well connected. Gl :-)

The new Chairman in place, GAD BERDUGO is a high flyer based in the US with a wealth of experience in Global Biotech, Corporate Development and US Capital Markets and so no doubt very well contected to any potential suitors. Excitement building!!!! In Eric we trust!!! Gla holders:-)

Ps initial Efficacy readout on the Dog Trial imminent!!! Gla ;-)

Nice one pickedpeck, undoubted near and mid term transformational UPside potential and prospects. Excitement building in anticipation of imminent Efficacy Data on the Dog Trial. Gl :-)